Rosa María A. A.
- Country
- Spain
- Department
- Institut de Recerca - CIM-Sant Pau
Research Overview
- Phase I Double-Blind, Randomized, Crossover Study on Pharmacokinetics and Safety of LB-0702 vs. Romiplostim in Healthy Volunteers
- Pharmacokinetic, Safety, Pharmacodynamic, and Immunogenicity Assessment of LT-01 vs. EU-Approved Omalizumab in Allergic Asthma, Rhinosinusitis, and Urticaria
- Bioequivalence Study of Paracetamol Orodispersible Tablets 500 mg Versus Apiretal 100 mg/mL Oral Solution in Fasting Healthy Volunteers
Data & Insights
Has run more than one trial at 4 of 11 partner sites.
Specializations
Allergy and Immunology
The investigator specializes in research involving antihistamine treatments and immunological responses, with particular focus on therapeutic solutions for various allergic conditions.
- Allergic rhinitis management
- Chronic spontaneous urticaria treatment
- Allergic asthma interventions
- Chronic rhinosinusitis with nasal polyps
Studies include evaluation of novel antihistamine formulations and biosimilar medications for allergic conditions.
Gastroenterology
The investigator conducts research in inflammatory bowel disease treatment, specifically focusing on therapeutic approaches for digestive tract conditions.
- Ulcerative colitis therapy
- Mesalazine formulation studies
Research includes investigation of oral medication efficacy and absorption under various conditions.
Clinical Pharmacology
The investigator focuses on pharmacokinetic and pharmacodynamic studies across various therapeutic areas and delivery methods.
- Bioequivalence assessment
- Drug absorption studies
- Novel drug delivery systems
- Comparative medication studies
Research encompasses evaluation of different drug formulations including orodispersible tablets and injectable medications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.